RAMM — Ramm Pharma Balance Sheet
0.000.00%
- CA$5.97m
- CA$5.47m
- CA$4.34m
- 45
- 60
- 41
- 47
Annual balance sheet for Ramm Pharma, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | R2021 October 31st | R2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | Interim Report | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 28 | 17.2 | 9.77 | 5.12 | 0.814 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.35 | 3.95 | 2.74 | 1.88 | 1.64 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 31.2 | 24.3 | 16.7 | 10.6 | 5.36 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.29 | 19.3 | 19.7 | 19 | 11.2 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 37.2 | 59.8 | 39.2 | 32.3 | 16.7 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.32 | 3.32 | 3.2 | 2.66 | 3.03 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Liabilities | 1.34 | 3.46 | 3.66 | 2.84 | 3.11 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 35.8 | 56.4 | 35.6 | 29.5 | 13.6 |
| Total Liabilities & Shareholders' Equity | 37.2 | 59.8 | 39.2 | 32.3 | 16.7 |
| Total Common Shares Outstanding |